Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus docetaxel versus placebo plus docetaxel as first-line treatment for HER2-negative metastatic breast cancer
2005-003862-40Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2005
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Bevacizumab + docetaxel with Placebo + docetaxel (2 arms). Primary endpoint: Progression-free survival. Started Nov 2005; status: completed.
02
Drugs
bevacizumabdocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-003862-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003862-40.